---
title: "REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293105409.md"
description: "A recent gene therapy treatment named sura-vec has shown lasting effectiveness in patients with wet AMD. The treatment, given only once, has maintained or even improved vision for up to 5 years in patients who previously needed frequent anti-VEGF injections. The doses used in the treatment were comparable to those being tested in current advanced studies. The results suggest promising long-term benefits for patients with wet AMD."
datetime: "2026-07-18T19:38:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293105409.md)
  - [en](https://longbridge.com/en/news/293105409.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293105409.md)
generator: "portal-rs"
---

# REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

A recent gene therapy treatment named sura-vec has shown lasting effectiveness in patients with wet AMD. The treatment, given only once, has maintained or even improved vision for up to 5 years in patients who previously needed frequent anti-VEGF injections. The doses used in the treatment were comparable to those being tested in current advanced studies. The results suggest promising long-term benefits for patients with wet AMD.

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)

## Related News & Research

- [Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting](https://longbridge.com/en/news/293104812.md)
- [Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments](https://longbridge.com/en/news/293231242.md)
- [Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patients](https://longbridge.com/en/news/296573642.md)
- [4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME](https://longbridge.com/en/news/296635019.md)
- [Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections](https://longbridge.com/en/news/296478792.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**